This budget-friendly Dell laptop is even more affordable at $150 off
Why you should buy the Dell Inspiron 15 3530 laptop
As an affordable device, you shouldn't expect the Dell Inspiron 15 3530 to challenge the best laptops in terms of specifications. However, if you need a machine for daily tasks such as building reports, doing online research, and participating in online meetings, it's going to be more than enough with its 13th-generation Intel Core i3 processor, integrated Intel UHD Graphics, and 8GB of RAM. The laptop also has a built-in FHD webcam so that you're crystal clear in video calls.
The Dell Inspiron 15 3530 has a pretty decent screen for a budget-friendly laptop — a 15.6-inch display with Full HD resolution and a 120Hz refresh rate, along with Dell's ComfortView technology that reduces blue light emissions to protect your eyes. The device also ships with a 512GB SSD, which should provide plenty of storage space for your apps and files, and it comes with Windows 11 Home pre-loaded so you won't have to deal with installing an operating system yourself.
There's no need to wait for Black Friday because Dell is already offering the shopping holiday's discounts in its Black Friday in July sale. Part of it is the Dell Inspiron 15 3530, an affordable but solid laptop that's down to just $250 from $400, for savings of $150. If you think this device will be perfect for your needs, you should finalize your transaction for it immediately as stocks may run out at any moment. Add the Dell Inspiron 15 3530 laptop to your cart and finish the checkout process right now to secure the discount.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Nutrien Declares Quarterly Dividend of US$0.545 per Share
SASKATOON, Saskatchewan, August 06, 2025--(BUSINESS WIRE)--Nutrien Ltd. (TSX and NYSE: NTR) announced today that its Board of Directors has declared a quarterly dividend of US$0.545 per share payable on October 17, 2025, to shareholders of record on September 29, 2025. Registered shareholders who are residents of Canada as reflected in Nutrien's shareholders register, as well as beneficial holders (i.e., shareholders who hold their common shares through a broker or other intermediary) whose intermediary is a participant in CDS Clearing and Depositary Services Inc. or its nominee, CDS & Co., will receive their dividend in Canadian dollars, calculated based on the Bank of Canada daily average exchange rate on September 29, 2025. Registered shareholders resident outside of Canada as reflected in Nutrien's shareholders register, including the United States, as well as beneficial holders whose intermediary is a participant in The Depository Trust Company or its nominee, Cede & Co., will receive their dividend in US dollars. However, registered shareholders of Nutrien may elect to change the currency of their dividend payments to US dollars or Canadian dollars, as applicable. In addition, Nutrien offers registered shareholders direct deposit by electronic funds transfer for dividend payments. Registered shareholders may elect to change the currency of their dividend and enroll for direct deposit by contacting, Nutrien's registrar and transfer agent, Computershare Investor Services Inc., directly (1-800-564-6253 or service@ Beneficial shareholders should contact their broker or other intermediary to determine the ability and necessary steps involved in an election to change the currency of their dividend payment. For further details, please visit All dividends paid by Nutrien are, pursuant to subsection 89(14) of the Income Tax Act (Canada), designated as eligible dividends. About Nutrien Nutrien is a leading global provider of crop inputs and services. We operate a world-class network of production, distribution and ag retail facilities that positions us to efficiently serve the needs of growers. We focus on creating long-term value by prioritizing investments that strengthen the advantages of our business across the ag value chain and by maintaining access to the resources and the relationships with stakeholders needed to achieve our goals. View source version on Contacts Jeff HolzmanSenior Vice President, Investor Relations and FP&A(306) 933-8545Contact us at: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Firefly Aerospace to price US IPO as it sets sights on a positive liftoff
By Pritam Biswas and Arasu Kannagi Basil (Reuters) -Northrop Grumman-backed Firefly Aerospace, the buzzy space technology startup that put a lander on the moon, is set to price its U.S. IPO later on Wednesday. In a nascent but rapidly growing commercial space industry, Firefly's IPO has attracted investor attention because it successfully landed its uncrewed Blue Ghost spacecraft on the moon in its first attempt in March. Cedar Park, Texas-based Firefly Aerospace is set to sell 16.2 million shares of its stock, priced between $41 and $43 apiece. This range was raised earlier this week, signaling strong demand. U.S. President Donald Trump's focus on commercializing space technology and safeguarding the national interests in space has attracted venture capital firms and billionaires. Elon Musk's SpaceX — the most valuable private company in the world — has become a critical part of the U.S. satellite network, even prompting a need across the government to look for more contractors. The U.S. government is betting that diversifying its contractor base will foster innovation and cut the huge costs of sending rockets to space, as well as reduce over-reliance on a single provider for critical missions. NASA's procurement process now includes new entrants such as Firefly Aerospace and Sierra Space, alongside legacy companies, leveraging commercial partnerships for lunar landers, space station modules and cargo deliveries. While space-related IPOs have been scarce in recent years, the tide is starting to turn in 2025. Firefly's listing comes on the heels of the successful New York flotations of space and defense firms Karman, AIRO Group and Voyager. As of Tuesday's close, shares of Karman have more than doubled from their offer price, while Voyager has gained 10%. "Given Firefly and the success of Voyager, I think you are going to see several more space-related companies test the waters of a public offering," said Ross Carmel, partner at law firm Sichenzia Ross Ference Carmel. TO THE MOON Formed in 2017, Firefly designs and manufactures small- to medium-lift launch vehicles, lunar landers and orbital vehicles. It had a backlog of roughly $1.1 billion and over 30 planned launches under contract as of March 31. While Houston-based Intuitive Machines' Odysseus lander was the first private lander to reach the moon last year, it made a lopsided touchdown, landing mostly intact but dooming many of its onboard instruments. Firefly's was the second, but its Blue Ghost spacecraft landed safely, reaching the moon's surface a month and a half after launching atop a SpaceX rocket from NASA's Kennedy Space Center in Florida. Last month, Firefly secured a $176.7 million contract to deliver five NASA payloads to the Moon's South Pole in 2029. Firefly was valued at more than $2 billion in a 2024 funding round. The company's backers include aerospace-focused private investment firm AE Industrial Partners. U.S. defense contractor Northrop Grumman, which invested $50 million into Firefly to aid the production of their jointly developed rocket, is one of three suppliers of solid rocket motors (SRMs) to the United States. Firefly is expected to begin trading on the Nasdaq under the ticker symbol "FLY" on Thursday.
Yahoo
9 minutes ago
- Yahoo
Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies
Novo Nordisk (NOVO, Financials) expanded its U.S. legal campaign against makers of unapproved versions of semaglutide the active ingredient in its blockbuster weight?loss and diabetes drugs Wegovy and Ozempic. The Danish drugmaker said Tuesday it filed 14 new lawsuits; the targets include telehealth providers, compounding pharmacies, and medical spas accused of selling compounded semaglutide under the fake guise of personalization. Warning! GuruFocus has detected 1 Warning Sign with NVO. The suits name firms such as Prism Aesthetics, Mochi Health, and Fella Health; some have also appeared in Eli Lilly's (LLY, Financials) litigation over knockoff versions of its weight?loss drug Zepbound. Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in some cases, the products allegedly contain illicit foreign?sourced active pharmaceutical ingredients. Compounders were temporarily allowed to produce semaglutide during a declared shortage; when the U.S. Food and Drug Administration ended that allowance, some companies shifted to offering personalized versions outside the approved drug label. Novo argues the approach violates state laws on corporate practice of medicine; it also raises safety concerns, as the copies have not been proven effective. Industry groups pushed back; Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said Novo's claims misrepresent the work of legitimate, state?licensed pharmacies. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
